CCL2 and cystic fibrosis: Scirpor et al. found that PPARG could inhibit NF-kB signaling pathway and then reduce the expression of CXC chemokine, monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 in the mouse model of cystic fibrosis [49].